Accession ID: MIRT001207 [miRNA, hsa-miR-155 ::
APC, target gene]
| pre-miRNA ID | hsa-mir-155 LinkOut: [miRBase ] |
|---|---|
| Description | Homo sapiens miR-155 stem-loop |
| Comment | Human mir-155 is predicted based on homology to a cloned miR from mouse (MIR:MI0000177) . |
| 2nd Structure of pre-miRNA |  |
| Mature miRNA | hsa-miR-155-3p |
|---|---|
| Mature Sequence | 43| CUCCUACAUAUUAGCAUUAACA |64 |
| Evidence | Experimental |
| Experiments | Cloned |
| Putative hsa-miR-155-3p Targets | LinkOut: [ TargetScanS 5.1 | MicroCosm | microRNA.org | miRecords | miRDB | miRo | miRNAMap 2.0 ] |
| Mature miRNA | hsa-miR-155-5p |
| Mature Sequence | 4| UUAAUGCUAAUCGUGAUAGGGGU |26 |
| Evidence | Experimental |
| Experiments | Cloned |
| Putative hsa-miR-155-5p Targets | LinkOut: [ TargetScanS 5.1 | MicroCosm | microRNA.org | miRecords | miRDB | miRo | miRNAMap 2.0 ] |
 |
| Gene Symbol | APC LinkOut: [ Entrez Gene | BioGPS | Wikipedia | iHop ] | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms | BTPS2, DP2, DP2.5, DP3, GS | ||||||||||||||||||||
| Description | adenomatous polyposis coli | ||||||||||||||||||||
| Transcript | NM_000038 LinkOut: [ RefSeq ] | ||||||||||||||||||||
| Other Transcripts | NM_001127510, NM_001127511 | ||||||||||||||||||||
| Expression | LinkOut: [ BioGPS ] | ||||||||||||||||||||
| KEGG Pathway |
hsa04310 Wnt signaling pathway - Homo sapiens (human) hsa04810 Regulation of actin cytoskeleton - Homo sapiens (human) hsa05200 Pathways in cancer - Homo sapiens (human) hsa05210 Colorectal cancer - Homo sapiens (human) hsa05213 Endometrial cancer - Homo sapiens (human) hsa05217 Basal cell carcinoma - Homo sapiens (human) |
||||||||||||||||||||
| Putative miRNA Targets on APC | LinkOut: [ TargetScan 5.1 | MicroCosm | miRNAMap 2.0 ] | ||||||||||||||||||||
| 3'UTR of APC (miRNA target sites are highlighted) |
>APC|NM_000038|3'UTR 1 TAAAAGAGAGGAAGAATGAAACTAAGAAAATTCTATGTTAATTACAACTGCTATATAGACATTTTGTTTCAAATGAAACT 81 TTAAAAGACTGAAAAATTTTGTAAATAGGTTTGATTCTTGTTAGAGGGTTTTTGTTCTGGAAGCCATATTTGATAGTATA 161 CTTTGTCTTCACTGGTCTTATTTTGGGAGGCACTCTTGATGGTTAGGAAAAAAATAGTAAAGCCAAGTATGTTTGTACAG 241 TATGTTTTACATGTATTTAAAGTAGCATCCCATCCCAACTTCCTTTAATTATTGCTTGTCTTAAAATAATGAACACTACA 321 GATAGAAAATATGATATATTGCTGTTATCAATCATTTCTAGATTATAAACTGACTAAACTTACATCAGGGAAAAATTGGT 401 ATTTATGCAAAAAAAAATGTTTTTGTCCTTGTGAGTCCATCTAACATCATAATTAATCATGTGGCTGTGAAATTCACAGT 481 AATATGGTTCCCGATGAACAAGTTTACCCAGCCTGCTTTGCTTTACTGCATGAATGAAACTGATGGTTCAATTTCAGAAG 561 TAATGATTAACAGTTATGTGGTCACATGATGTGCATAGAGATAGCTACAGTGTAATAATTTACACTATTTTGTGCTCCAA 641 ACAAAACAAAAATCTGTGTAACTGTAAAACATTGAATGAAACTATTTTACCTGAACTAGATTTTATCTGAAAGTAGGTAG 721 AATTTTTGCTATGCTGTAATTTGTTGTATATTCTGGTATTTGAGGTGAGATGGCTGCTCTTTTATTAATGAGACATGAAT 801 TGTGTCTCAACAGAAACTAAATGAACATTTCAGAATAAATTATTGCTGTATGTAAACTGTTACTGAAATTGGTATTTGTT 881 TGAAGGGTCTTGTTTCACATTTGTATTAATAATTGTTTAAAATGCCTCTTTTAAAAGCTTATATAAATTTTTTTCTTCAG 961 CTTCTATGCATTAAGAGTAAAATTCCTCTTACTGTAATAAAAACAATTGAAGAAGACTGTTGCCACTTAACCATTCCATG 1041 CGTTGGCACTTATCTATTCCTGAAATTTCTTTTATGTGATTAGCTCATCTTGATTTTTAATATTTTTCCACTTAAACTTT 1121 TTTTTCTTACTCCACTGGAGCTCAGTAAAAGTAAATTCATGTAATAGCAATGCAAGCAGCCTAGCACAGACTAAGCATTG 1201 AGCATAATAGGCCCACATAATTTCCTCTTTCTTAATATTATAGAATTCTGTACTTGAAATTGATTCTTAGACATTGCAGT 1281 CTCTTCGAGGCTTTACAGTGTAAACTGTCTTGCCCCTTCATCTTCTTGTTGCAACTGGGTCTGACATGAACACTTTTTAT 1361 CACCCTGTATGTTAGGGCAAGATCTCAGCAGTGAAGTATAATCAGCACTTTGCCATGCTCAGAAAATTCAAATCACATGG 1441 AACTTTAGAGGTAGATTTAATACGATTAAGATATTCAGAAGTATATTTTAGAATCCCTGCCTGTTAAGGAAACTTTATTT 1521 GTGGTAGGTACAGTTCTGGGGTACATGTTAAGTGTCCCCTTATACAGTGGAGGGAAGTCTTCCTTCCTGAAGGAAAATAA 1601 ACTGACACTTATTAACTAAGATAATTTACTTAATATATCTTCCCTGATTTGTTTTAAAAGATCAGAGGGTGACTGATGAT 1681 ACATGCATACATATTTGTTGAATAAATGAAAATTTATTTTTAGTGATAAGATTCATACACTCTGTATTTGGGGAGGGAAA 1761 ACCTTTTTAAGCATGGTGGGGCACTCAGATAGGAGTGAATACACCTACCTGGTGCCTTGAAAATCACATCAAGTAGTTAA 1841 TTATCTACCCCTTACCTGTGTTTATAACTTCCAGGTAATGAGAATGATTTTTTTTAAAGCTAAAATGCCAGTAAATAAAA 1921 GTGCTATGACTTGAGCTAAGATATTTGACTCCAATGCCTGTACTGTGTCTACTGCACCACTTTGTAAACACTTCAATTTA 2001 CTATCTTTGAAATGATTGACCTTTAAATTTTTGCCAAATGTTATCTGAAATTGTCTATGAATACCATCTACTTCTGTTGT 2081 TTTCCCAGGCTTCCATAAACAATGGAGATACATGCA Target sites Provided by authors Predicted by miRanda |
||||||||||||||||||||
| miRNA-target interactions (Predicted by miRanda) |
|
| miRNA:Target | hsa-miR-155 :: APC [ Functional MTI ] | ||||||
|---|---|---|---|---|---|---|---|
| Validation Method | Luciferase reporter assay , Western blot | ||||||
| Conditions | HEK293 | ||||||
| Location of target site | 3'UTR | ||||||
| Tools used in this research | miRBase Target Database | ||||||
| Original Description (Extracted from the article) | ... As expected, these AMOs all were able to significantly increase luciferase activities (Figure 1G), presumably by knocking down the endogenous miR-21, miR-155 and miR-17-5p in HeLa cells ... - Lu, Y. Xiao, J. Lin, H. Bai, Y. Luo, X. et al., 2009, Nucleic Acids Res. |
||||||
| miRNA-target interactions (Provided by authors) |
|
||||||
| Article |
- Lu, Y.
Xiao, J.
Lin, H.
Bai, Y.
Luo, X. et al. - Nucleic Acids Res, 2009
Anti-miRNA antisense inhibitors (AMOs) have demonstrated their utility in miRNA research and potential in miRNA therapy. Here we report a modified AMO approach in which multiple antisense units are engineered into a single unit that is able to simultaneously silence multiple-target miRNAs, the multiple-target AMO or MTg-AMO. We validated the technique with two separate MTg-AMOs: anti-miR-21/anti-miR-155/anti-miR-17-5p and anti-miR-1/anti-miR-133. We first verified the ability of the MTg-AMOs to antagonize the repressive actions of their target miRNAs using luciferase reporter activity assays and to specifically knock down the levels of their target miRNAs using real-time RT-PCR methods. We then used the MTg-AMO approach to identify several tumor suppressors-TGFBI, APC and BCL2L11 as the target genes for oncogenic miR-21, miR-155 and miR-17-5p, respectively, and two cardiac ion channel genes HCN2 (encoding a subunit of cardiac pacemaker channel) and CACNA1C (encoding the alpha-subunit of cardiac L-type Ca(2+) channel) for the muscle-specific miR-1 and miR-133. We further demonstrated that the MTg-AMO targeting miR-21, miR-155 and miR-17-5p produced a greater inhibitory effect on cancer cell growth, compared with the regular single-target AMOs. Moreover, while using the regular single-target AMOs excluded HCN2 as a target gene for either miR-1 or miR-133, the MTg-AMO approach is able to reveal HCN2 as the target for both miR-1 and miR-133. Our findings suggest the MTg-AMO as an improved approach for miRNA target finding and for studying function of miRNAs. This approach may find its broad application for exploring biological processes involving multiple miRNAs and multiple genes.
LinkOut: [PMID: 19136465]
|